Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C L Duncan

Showing results (41-50 of 45) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 45 results.
Journal of General Internal Medicine|November 1, 1989
Training physicians about smoking cessation: a controlled trial in private practiceS R Cummings, R J Richard, C L Duncan, et al.
Antimicrobial Agents and Chemotherapy|October 19, 2000
Fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae: contributions of type II topoisomerase mutations and efflux to levels of resistanceD J Bast, D E Low, C L Duncan, et al.
Journal of Chemotherapy (Florence, Italy)|October 10, 2006
Relative potential for selection of quinolone-resistance-determining-region mutations in Streptococcus pneumoniae by gemifloxacin, gatifloxacin and moxifloxacinJ C S De Azavedo, C L Duncan, L Kilburn, et al.
Journal of Chemotherapy (Florence, Italy)|February 3, 2007
Short-course therapy of gemifloxacin effective against pneumococcal pneumonia in miceD J Bast, L Dresser, C L Duncan, et al.
Antimicrobial Agents and Chemotherapy|March 19, 2002
Activity of BMS-284756, a novel des-fluoro(6) quinolone, against Staphylococcus aureus, including contributions of mutations to quinolone resistanceD E Low, M Muller, C L Duncan, et al.
Pageof 5

Showing results (41-50 of 45) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 45 results.
Journal of General Internal Medicine|November 1, 1989
Training physicians about smoking cessation: a controlled trial in private practiceS R Cummings, R J Richard, C L Duncan, et al.
Antimicrobial Agents and Chemotherapy|October 19, 2000
Fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae: contributions of type II topoisomerase mutations and efflux to levels of resistanceD J Bast, D E Low, C L Duncan, et al.
Journal of Chemotherapy (Florence, Italy)|October 10, 2006
Relative potential for selection of quinolone-resistance-determining-region mutations in Streptococcus pneumoniae by gemifloxacin, gatifloxacin and moxifloxacinJ C S De Azavedo, C L Duncan, L Kilburn, et al.
Journal of Chemotherapy (Florence, Italy)|February 3, 2007
Short-course therapy of gemifloxacin effective against pneumococcal pneumonia in miceD J Bast, L Dresser, C L Duncan, et al.
Antimicrobial Agents and Chemotherapy|March 19, 2002
Activity of BMS-284756, a novel des-fluoro(6) quinolone, against Staphylococcus aureus, including contributions of mutations to quinolone resistanceD E Low, M Muller, C L Duncan, et al.
Pageof 5